Von Willebrand factor to the rescue

Blood

Volumn 113, Issue 21, 2009, Pages 5049-5057

  De Meyer, Simon F ^a   Deckmyn, Hans ^a   Vanhoorelbeke, Karen ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; RECOMBINANT INTERLEUKIN 11; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILFACTIN; ARGIPRESSIN[1 DEAMINO]; INTERLEUKIN 11;

BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG COST; DRUG SYNTHESIS; FIBRINOGEN BLOOD LEVEL; FLUID RETENTION; FLUSHING; GENE THERAPY; HEADACHE; HEART ATRIUM ARRHYTHMIA; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INFECTION RISK; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; TACHYCARDIA; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; GENE THERAPY; HUMANS; INTERLEUKIN-11; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 67149132162     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-165621     Document Type: Review

References (107)

1. von Willebrand EA. Hereditär pseudohemofili. Fin Laekaresaellsk Hand. 1926;68:87-112.
2. Nilsson IM, Blomback M, Von FI. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand. 1957;159:35-57.
3. Nilsson IM, Blomback M, Jorpes E, et al. von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand. 1957;159:179-188.
4. Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A. 1985;82:6394-6398. (Pubitemid 16230519)
5. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5:1839-1847.
6. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998;273:10396-10401. (Pubitemid 28227648)
7. Bienkowska J, Cruz M, Atiemo A, Handin R, Liddington R. The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif. J Biol Chem. 1997;272:25162-25167. (Pubitemid 27415701)
8. Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost. 1996;75:950-958. (Pubitemid 26355353)
9. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem. 1991;196:369-375.
10. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost. 2007;5:1363-1370. (Pubitemid 46965360)
11. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ib alpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A. 2004;101:10578-10583. (Pubitemid 38955784)
12. Ulrichts H, Udvardy M, Lenting PJ, et al. Shielding of the A1 domain by the D′D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem. 2006; 281:4699-4707. (Pubitemid 43847729)
13. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-297. (Pubitemid 26040846)
14. Doggett TA, Girdhar G, Lawshe A, et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond. Biophys J. 2002;83:194-205. (Pubitemid 34694731)
15. Mody NA, Lomakin O, Doggett TA, Diacovo TG, King MR. Mechanics of transient platelet adhesion to von Willebrand factor under flow. Biophys J. 2005;88:1432-1443. (Pubitemid 40975970)
16. Yago T, Lou J, Wu T, et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest. 2008;118:3195-3207.
17. Yago T, Lou J, Wu T, et al. Platelet glycoprotein lb alpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest. 2008;118:3195-3207.
18. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112:957-964.
19. Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest. 1985;76:1491-1500.
20. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-1666.
21. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654-1661.
22. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990;87:6306-6310. (Pubitemid 20259006)
23. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112:1704-1712.
24. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-459. (Pubitemid 17022013)
25. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123:893-898.
26. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160-174. (Pubitemid 30601459)
27. Sadler JE. A revised classification of von Willebrand disease: for the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71:520-525.
28. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2114. (Pubitemid 44403432)
29. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4:774-782.
30. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109:145-154. (Pubitemid 46053055)
31. Goodeve A. Genetics of type 1 von Willebrand disease. Curr Opin Hematol. 2007;14:444-449. (Pubitemid 47457634)
32. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14:171-232.
33. O'Brien LA, Sutherland JJ, Weaver DF, Lillicrap D. Theoretical structural explanation for Group I, Group II, type 2A von Willebrand disease mutations. J Thromb Haemost. 2005;3:796-797. (Pubitemid 41647895)
34. Lillicrap D. von Willebrand disease - phenotype versus genotype: deficiency versus disease. Thromb Res. 2007;120(suppl 1):S11-S16. (Pubitemid 46874547)
35. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113:526-534.
36. Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost. 2001;86:848-854. (Pubitemid 32834196)
37. Federici AB, Rand JH, Mannucci PM. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J. 2001;2:358-362.
38. Cash JD, Gader AM, da Costa J. Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol. 1974;27:363-364.
39. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol. 1975;30:81-93.
40. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1:682-689.
41. Jacquemin M, Neyrinck A, Hermanns MI, et al. FVIII production by human lung microvascular endothelial cells. Blood. 2006;108:515-517. (Pubitemid 44061350)
42. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer. 2006;46:547-553.
43. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82:87-93.
44. Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood. 1985;66:796-802. (Pubitemid 15242461)
45. Rodeghiero F, Castaman G, Di Bona E, et al. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intraplatelet von Willebrand factor. Eur J Haematol. 1988;40:163-167. (Pubitemid 18098114)
46. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111:3531-3539.
47. Millar CM, Riddell AF, Brown SA, et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost. 2008;99:916-924.
48. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982;59:1272-1278. (Pubitemid 12074858)
49. Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost. 2002;87:990-996.
50. Franchini M, Krampera M, Veneri D. Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes. Thromb Haemost. 2003;90:963-964. (Pubitemid 37427871)
51. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med. 1988;318:121. (Pubitemid 18029309)
52. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol. 1988;28:63-65. (Pubitemid 18153444)
53. Budde U, Metzner HJ, Muller HG. Comparative analysis and classification of von Willebrand factor/ factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost. 2006;32:626-635. (Pubitemid 44453024)
54. Mazurier C. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease. Semin Thromb Hemost. 2006;32:529-536. (Pubitemid 44157392)
55. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990: Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1994;7:279-286.
56. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral-hepatitis in a United-States hemophilic population. Blood. 1993;81:412-418.
57. Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med. 2005;257:224-237. (Pubitemid 40342125)
58. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88:378-379. (Pubitemid 35021592)
59. Castillo R, Monteagudo J, Escolar G, et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood. 1991;77:1901-1905.
60. Boda Z, Pfliegler G, Harsfalvi J, Rak K. Treatment of the severe bleeding episode in type III von Willebrand's disease by simultaneous administration of cryoprecipitate and platelet concentrate. Blood Coagul Fibrinolysis. 1991;2:775-777.
61. Castillo R, Escolar G, Monteagudo J, et al. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion. 1997;37:785-790. (Pubitemid 27369128)
62. Denis CV, Kwack K, Saffaripour S, et al. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood. 2001;97:465-472. (Pubitemid 32060332)
63. Olsen EH, McCain AS, Merricks EP, et al. Comparative response of plasma VWF in dogs to upregulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood. 2003;102:436-441.
64. Ragni MV, Jankowitz RC, Chapman HL, et al. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia. 2008;14:968-977.
65. Jankowitz RC, Ragni MV, Chapman HL, et al. Recombinant interleukin-11 (rhIL-11) in women with refractory menorrhagia and von Willebrand disease [abstract]. Blood. 2008;112:Abstract 1210.
66. Gordon MS, Caskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin- 11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996;87:3615-3624.
67. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607-3614. (Pubitemid 26129588)
68. De Meyer SF, Vanhoorelbeke K, Chuah MK, et al. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood. 2006;107:4728-4736. (Pubitemid 43882623)
69. Mayadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH: importance of the propolypeptide and free sulfhydryls. J Biol Chem. 1989;264:13497-13503.
70. Verweij CL, Hart M, Pannekoek H. Proteolytic cleavage of the precursor of von Willebrand factor is not essential for multimer formation. J Biol Chem. 1988;263:7921-7924. (Pubitemid 18161484)
71. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992;89:3531-3535.
72. Purvis AR, Gross J, Dang LT, et al. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc Natl Acad Sci U S A. 2007;104:15647-15652. (Pubitemid 350035354)
73. Hannah MJ, Williams R, Kaur J, Hewlett LJ, Cutler DF. Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol. 2002;13:313-324.
74. Plaimauer B, Schlokat U, Turecek PL, et al. Recombinant von Willebrand factor: preclinical development. Semin Thromb Hemost. 2001;27:395-403. (Pubitemid 32802895)
75. Turecek PL, Mitterer A, Mathiessen HP, et al. Downstream processing and characterization of a novel recombinant von Willebrand factor product: Proceedings of the European Workshop on von Willebrand Factor and von Willebrand Disease, Antwerp, Belgium. 2008;167.
76. Turecek PL, Matthiessen HP, Mitterer A, et al. Biochemical and functional characterization of a serum-free rVWF drug candidate [abstract]. Blood. 2006;108:Abstract 1017.
77. Nichols TC, Merricks E, Muchitsch EM, et al. Pharmacokinetics of rVWF in dogs and mice with severe VWD [abstract]. J Thromb Haemost. 2007;5(suppl 2).Abstract P-W-197.
78. Turecek PL, Scheiflinger F, Siekmann J, et al. Biochemical and functional characterization of PEGylated rVWF [abstract]. Blood. 2006;108:Abstract 1021.
79. Turecek PL, Siekmann J, Weber A, et al. Modification of rVWF with polysialic acid: biochemical and functional characterization in mice with VWD [abstract]. Blood. 2006;108:Abstract 1001.
80. Barlow JH, Stapley J, Ellard DR. Living with haemophilia and von Willebrand's: a descriptive qualitative study. Patient Educ Couns. 2007;68:235-242. (Pubitemid 47539839)
81. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111:1236-1239. (Pubitemid 32104944)
82. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia. 2004;10(suppl 4):169-176. (Pubitemid 40045438)
83. Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin. Haemophilia. 2008;14:21-30.
84. Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia. 2003;9:292-297. (Pubitemid 36622031)
85. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia. 2008;14(suppl 5):47-53.
86. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res. 2006;118(suppl 1):S9-S11.
87. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16(suppl 1):S23-S26. (Pubitemid 40756405)
88. Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand's disease: an Italian cohort study [abstract]. Blood. 2005;106:Abstract 1782.
89. De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K. False positive results in chimeraplasty for von Willebrand disease. Thromb Res. 2007;119:93-104. (Pubitemid 44724919)
90. Lenting PJ, de Groot PG, De Meyer SF, et al. Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF. Blood. 2007;109:2267-2268.
91. Pergolizzi RG, Jin GC, Chan D, et al. Correction of a murine model of von Willebrand disease by gene transfer. Blood. 2006;108:862-869. (Pubitemid 44154618)
92. De Meyer SF, Vandeputte N, Pareyn I, et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28:1621-1626.
93. Lin Y, Chang L, Solovey A, et al. Use of blood out-growth endothelial cells for gene therapy for hemophilia A. Blood. 2002;99:457-462. (Pubitemid 34533079)
94. Matsui H, Shibata M, Brown B, et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007;25:2660-2669. (Pubitemid 47582759)
95. Marx I, Lenting PJ, Adler T, et al. Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol. 2008;28:419-424.
96. Marx I, Christophe OD, Lenting PJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPI-IbIIIa. Blood. 2008;112:603-609.
97. Huang J, Roth R, Heuser JE, Sadler JE. Integrin alpha (v) beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood. 2009;113:1589-1597.
98. Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood. 2004;103:2150-2156. (Pubitemid 38326232)
99. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007: an update. J Gene Med. 2007;9:833-842.
100. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987;79:1459-1465.
101. Mannucci PM, Tamaro G, Narchi G, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol. 1987;39:467-470. (Pubitemid 18002930)
102. Shi Q, Wilcox DA, Fahs SA, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007;5:352-361. (Pubitemid 46139461)
103. Shi Q, Fahs SA, Wilcox DA, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008;112:2713-2721.
104. Nichols TC, Samama CM, Bellinger DA, et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A. 1995;92:2455-2459.
105. Mannucci PM. Management of von Willebrand disease in developing countries. Semin Thromb Hemost. 2005;31:602-609. (Pubitemid 41642573)
106. Srivastava A. von Willebrand disease in the developing world. Semin Hematol. 2005;42:36-41. (Pubitemid 40127268)
107. Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost. 2005;31:569-576. (Pubitemid 41642571)